EGFR and diabetes mellitus: Taking into account the more favorable profile given by the addition of irinotecan to the anti-EGFR treatment in patients with DM, and the increased risk posed by the association of antiangiogenic treatment with oxaliplatin, it is worth investigating whether the use of irinotecan could be extended.